RPC Contact:

Dilek Mir Director, Business Development & Investor Relations dmir@radient­pharma.com

(Tel:) 714.881.0244

Radient Pharmaceuticals Appoints Dilek Mir As Director of Business

Development and Investor Relations

__

TUSTIN, CA—July 6, 2011 ­ Radient Pharmaceuticals Corporation “the Company” or “RPC” (OTCQX:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has appointed Dilek Mir as Director of Business Development and Investor Relations. Ms. Mir brings to RPC extensive industry knowledge in both investor relations and medical diagnostics. In this position Ms. Mir will oversee investor relations, new business development, reimbursement strategy, and intellectual property strategy.

Ms. Mir has been an investor relations professional for 13 years. As an executive at Los Angeles and New York based investor relations agencies, she has advised and represented dozens of publicly traded technology and healthcare companies. Healthcare clients have included leaders in their product categories, as well as emerging companies subsequently sold to global healthcare giants.

She has been engaged in technology transfer in both the healthcare and high­tech fields. As an entrepreneur she is founder of ProteaSure, developer of a proteomic in­vitro diagnostic for endometrial cancer. Prior, she had founded, built and sold Polyglot International, the first privately owned language training firm in Moscow, which served over a dozen Fortune 500 clients. Ms. Mir sold Polyglot to Nord Anglia PLC, a global leader in private education.

She serves as Managing Director at Corporate Profile, a boutique New York based investor relations firm. Ms. Mir received her Bachelor of Science in Finance and Political Science from the University of Massachusetts and her M.B.A. from Babson College in Wellesley, Massachusetts.

“Dilek’s blend of expertise in both investor relations and medical diagnostics will support our efforts for highly transparent and effective communications while we also putting greater resources into new business development,” stated Radient Pharmaceuticals Chairman and CEO Douglas MacLellan. “We are grateful to Kristine Szarkowitz, our former investor relations director, for her great work and professionalism.”

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient­pharma.comor e­mail info@radient­pharma.com. For Investor Relations contact Dilek Mir at: ir@radient­pharma.comor 714­881­0244.

The following table is intended to provide the latest information on RPC’s business metrics.

RPC’s Business Metrics

Cash on hand: $1.4 million*

*Approximate amount as of July 5, 2011

Shares Outstanding: 174 million*

*Approximate number as of July 5, 2011 and there are 200 million shares fully authorized.

Outstanding Warrants & Options: 138.7 million*

*Approximate number as of July 5, 2011

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA